Table 2.
Summary of Correlation of Mean Platelet Volume (MPV) with Tumor
| Disease Model/Patient Type | Comments | Ref. |
|---|---|---|
| CRC | MPV may be useful markers in diagnostic and early recognition of different stages of CRC; additionally, combined all with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have stronger diagnostic efficacy. | Stojkovic Lalosevic M et al,27 |
| CRC | MPV/PC may be helpful in the diagnosis of CRC. | Wu YY et al,26 |
| CRC | Serum MPV or platelet distribution width (PDW) content may be used as a predictor of postoperative sepsis in patients with CRC. | Li XT et al,44 |
| CRC | Elevated MPV might act as a marker of prognosis and therapeutic target for CRC. | Li N et al,45 |
| metastatic colorectal cancer (mCRC) | The baseline MPV level may act as a predictive factor for survival in mCRC patients undergoing standard chemotherapy. | Chang J et al,46 |
| Colon cancer (CC) | Increased MPV and decreased platelet distribution width (PDW) appear to be poor prognostic factors in the early stages of, especially in CC patients with stage III disease. | Sakin A et al,47 |
| Malignant thyroid nodule | MPV can be regarded as an auxiliary diagnostic tool to distinguish malignant and benign thyroid nodules. | Sit M et al,48 |
| Pancreatic cancer (PC) | MPV elevated is associated with poor survival in PC patients with concurrent liver metastases. | Yin JB et al,49 |
| Pancreatic ductal adenocarcinoma (PDAC) | MPV independently predicts poor survival in PDAC patients with Type 2 diabetes mellitus (T2DM). | Yin JB et al,50 |
| Gallbladder cancer (GBC) | MPV and PDW are available parameters for early detection of GBC. | Zhang X et al,51 |
| Hepatocellular carcinoma (HCC) | Lower MPV is a risk indicator of HCC patients survival outcomes after liver transplantation (LT). | Zhang AB et al,52 |
| HCC | Thrombocytopenia and higher MPV are associated with better outcome in patients with advanced HCC. | Scheiner B et al,21 |
| Osteosarcoma | The high preoperative MPV/plateletcrit ratio may serve as an independent prognostic factor for a favorable prognosis in male osteosarcoma patients. | Gou B et al,53 |
| Esophageal cancer | Reduced MPV is associated with worse survival outcome in esophageal cancer. | Shen W et al,54 |
| Esophageal squamous cell carcinoma (ESCC) | Decreased MPV and mean platelet volume/platelet count ratio (MPR) are significantly associated with locally advanced ESCC. These may help the screening and risk stratification of locally advanced ESCC. | Sun SY et al,55 |
| ESCC | COP-MPV is a promising predictor for postoperative survival in ESCC patients. | Zhang F et al,56 |
| Lung cancer | Increased platelet count and decreased MPV are the poor prognosis of lung cancer patients, and platelet count is also associated with bone, soft tissue, lymph node metastasis and malignant pleural effusion. | Ohuchi M et al,22 |
| Non-small cell lung cancer (NSCLC) | MPV may represent one of the easiest measuring tools as an independent prognostic marker for survival in locally advanced NSCLC. | Sakin A et al,57 |
| NSCLC | The increased MPV level may be used as a prognostic biomarker to estimate for poor overall survival in patients with NSCLC. | Omar M et al,58 |
| Diffuse large B-cell lymphoma (DLBCL) | Low baseline MPV is an independent prognostic marker of poor outcome in patients with DLBCL. | Zhou S et al,59 |
| DLBCL | The pre-chemotherapy MPV value is a cheap and available parameter that may be a useful prognostic marker for a significant risk of venous thromboembolism (VTE) and inferior survival rates in patients with DLBCL. | Rupa-Matysek J et al,60 |
| Multiple myeloma (MM) | The low MPV is correlated with poor prognosis in patients with MM and may serve as an important indicator for disease progression and prognosis of patients with MM. | Gao P et al,61 |
| MM | The low MPV predicted an unfavorable prognosis in patients with MM. | Zhuang Q et al,62 |
| Renal cell carcinoma (RCC) | Reduced MPV is identified as an independent predictor of adverse clinical outcome in RCC. | Yun ZY et al,63 |
| Clear cell renal cell carcinoma (ccRCC) | The mean platelet volume-to-lymphocyte ratio (MPVLR) is an easily obtainable prognostic marker for overall survival in nonmetastatic ccRCC patients treated with nephrectomy. | Życzkowski M et al,64 |
| Invasive breast cancer (IBC) | High pre-treatment MPV level in IBC patients was a potential predictive factor. | Gu M et al,65 |
| BC | The combination of preoperative D-Dimer and MPV improves the predictive power of postoperative deep venous thrombosis risk in BC patients. | Cui LN et al,66 |
| Breast cancer with bone metastases | MPV can be used to predict the development of isolated bone metastases patients with breast cancer. | Tanriverdi O et al,67 |
| Primary malignant bone tumor | MPV and MPV/PLT ratios can be used as a diagnostic support parameter in primary malignant bone tumors, but have no prognostic value. | Sökmen FC et al,68 |
| Oral squamous cell carcinoma (OSCC) | Count of platelet (COP) -MPV score is a simple and a more effective prognostic factor than other considered factors in predicting the prognosis of OSCC patients. | Park JW et al,69 |
| Resectable gastric cancer | MPV measurement can provide important diagnostic and prognostic results in patients with resectable gastric cancer. | Shen XM et al,70 |
| Prostate cancer | The combined use of prostate specific antigen (PSA), MPV, and platelet distribution width (PDW) may be clinically useful in distinguishing between prostate cancer (PCa) and benign prostate hyperplasia (BPH). | Fu S et al,71 |
| Laryngeal squamous cell carcinoma (LSCC) | Preoperative hyperfibrinogenemia, increased MPV and NLR were associated with reduced prognosis in patients with LSCC. | Sheng X et al,72 |
| Ovarian cancer | Combinations of the markers red cell distribution width (RDW), MPV, and CA125 may improve the differential diagnosis of ovarian cancer and benign ovarian cancers. | Qin YY et al,73 |
| Differentiated thyroid carcinoma (DTC) | Their findings suggest that neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and MPV changes indicate systemic inflammation that occurs after radioiodine (RAI) therapy because of thyroid remnant tissue ablation. | Demir Y et al,74 |